Want to see AU:1AI full AI Analyst Report?
1AI Stock Chart & Stats
AU$0.02
AU$0.00(0.00%)
At close: 4:00 PM EDT
AU$0.02
AU$0.00(0.00%)
Day’s Range― - ―
52-Week Range<AU$0.01 - AU$0.02
Previous CloseN/A
Volume31.97M
Average Volume (3M)2.98M
Market Cap
AU$26.33M
Enterprise ValueAU$17.71M
Total Cash (Recent Filing)AU$1.88M
Total Debt (Recent Filing)AU$0.00
Price to Earnings (P/E)26.0
Beta0.15
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)<0.01
Shares Outstanding2,025,571,000
10 Day Avg. Volume1,972,597
30 Day Avg. Volume2,982,772
Financial Highlights & Ratios
PEG Ratio0.11
Price to Book (P/B)3.79
Price to Sales (P/S)0.00
P/FCF Ratio-10.74
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
No Debt / Low LeverageAbsence of debt reduces fixed financing costs and insolvency risk, preserving runway for R&D spending. For a clinical-stage biotech, low leverage improves flexibility to raise non-debt funding and withstand trial timelines, a durable advantage over the next several months.
Clinical-stage Encapsulated Cell Therapy PlatformOwning a specialized encapsulated cell therapy platform creates structural differentiation and high technical barriers to entry. Clinical-stage programs targeting chronic diseases can generate sustained value if trials progress, supporting long-term competitive positioning in a niche biotech segment.
Improving Net Loss TrendA material narrowing of net losses signals improving cost control or program efficiency and reduces short-term funding pressure. If sustained, this trajectory can extend runway and lower future capital needs, a durable operational improvement over coming months.
Bears Say
Effectively No RevenueAbsence of meaningful revenue indicates the business is pre-commercial and lacks validated recurring cashflows. This structural reliance on future trial success and external capital increases execution risk and implies no internal funding source over the medium term.
Persistent Negative Operating And Free Cash FlowConsistent operating and free cash flow deficits demonstrate ongoing cash burn and dependency on financing. Over a 2–6 month horizon this constrains strategic optionality, likely necessitating capital raises that can dilute shareholders or disrupt program timelines.
Declining Equity And Assets (capital Erosion)Declining equity and shrinking assets reflect cumulative losses and reduced balance sheet resilience, limiting ability to support trials or secure favorable partnership terms. This structural weakening heightens vulnerability to funding shocks in the medium term.
Living Cell Technologies News
1AI FAQ
What was Living Cell Technologies Ltd.’s price range in the past 12 months?
Living Cell Technologies Ltd. lowest share price was <AU$0.01 and its highest was AU$0.02 in the past 12 months.
What is Living Cell Technologies Ltd.’s market cap?
Living Cell Technologies Ltd.’s market cap is AU$26.33M.
When is Living Cell Technologies Ltd.’s upcoming earnings report date?
Living Cell Technologies Ltd.’s upcoming earnings report date is Aug 27, 2026 which is in 56 days.
How were Living Cell Technologies Ltd.’s earnings last quarter?
Living Cell Technologies Ltd. released its earnings results on Feb 27, 2026. The company reported AU$0 earnings per share for the quarter, the consensus estimate of N/A by AU$0.
Is Living Cell Technologies Ltd. overvalued?
According to Wall Street analysts Living Cell Technologies Ltd.’s price is currently Overvalued.
Does Living Cell Technologies Ltd. pay dividends?
Living Cell Technologies Ltd. does not currently pay dividends.
What is Living Cell Technologies Ltd.’s EPS estimate?
Living Cell Technologies Ltd.’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Living Cell Technologies Ltd. have?
Living Cell Technologies Ltd. has 2,025,571,000 shares outstanding.
What happened to Living Cell Technologies Ltd.’s price movement after its last earnings report?
Living Cell Technologies Ltd. reported an EPS of AU$0 in its last earnings report, expectations of N/A. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Living Cell Technologies Ltd.?
Currently, no hedge funds are holding shares in AU:1AI
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Living Cell Technologies Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Blogger Sentiment
Bullish
AU:1AI Sentiment 100%
Sector Average ―
Sector Average ―
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Fundamentals
Return on Equity
-49.25%
Trailing 12-Months
Asset Growth
-15.04%
Trailing 12-Months
Company Description
Living Cell Technologies Ltd.
Algorae Pharmaceuticals Limited, a company established in 1987 and based in Melbourne, Australia, focuses on pioneering pharmaceutical development. Known as Living Cell Technologies Limited until its rebranding in September 2023, the firm primarily conducts research and innovation in living cell technologies within New Zealand. Its development portfolio includes AI-116, a novel combination treatment pairing donepezil with cannabidiol, designed to address various forms of dementia, such as Alzheimer's disease. Another key candidate is AI-168, a unique blend of a cannabinoid and an existing, off-patent drug component, aimed at managing cardiovascular conditions like hypertension. Additionally, Algorae is progressing with NTCELL, an alginate-encapsulated product for the treatment of Parkinson's disease. The company is also collaborating with the University of New South Wales to create AlgaraeOS, an advanced drug discovery platform that utilizes artificial intelligence protocols and extensive data analytics to optimize drug identification and development processes.
Technical Analysis
Cynata Therapeutics Limited
―
Mesoblast Limited
―
Orthocell Ltd
―
Tissue Repair Ltd
―
Regeneus Ltd.
―
Options Prices
Currently, No data available
---